Attorney Docket 051530-5006 U.S. National Phase of PCT/US03/17410 Page 3

## Remarks

The amendments to the specification are being made to update the priority data and to add the requisite abstract of the disclosure. Accordingly, Applicants submit that no new matter has been added by these amendments.

Except for issue fees payable under 37 C.F.R. 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a constructive petition for extension of time in accordance with 37 C.F.R. 1.136(a)(3).

Dated: November 29, 2004 Morgan, Lewis & Bockius LLP Customer No. 09629 1111 Pennsylvania Avenue Washington, D.C. 20004 202-739-3000 Respectfully submitted, Morgan, Lewis & Bockius LLP

Robert Smyth

Registration No. 50,801

## **Abstract of the Disclosure**

This invention includes compositions and methods for combination chemotherapy, particularly involving at least one chemotherapeutic agent used in combination with chlorotoxin or a derivative thereof.